{"title":"Morusin attenuates LPS-induced inflammation and oxidative stress in lung epithelial cells by inhibiting NLRP3 inflammasome activation.","authors":"Yan Li, Li Zhang","doi":"10.15586/aei.v53i4.1365","DOIUrl":null,"url":null,"abstract":"<p><p>Acute lung injury (ALI) is a pulmonary disorder characterized by severe lung tissue damage and inflammation. Morusin (a flavone, a type of flavonoid; C<sub>25</sub>H<sub>24</sub>O<sub>6</sub>), a flavonoid isolated from mulberry root bark, possesses notable anti-inflammatory and antioxidant properties. However, its regulatory effects on ALI progression remain unclear. This study aimed to investigate whether morusin could mitigate the development of ALI. Morusin was shown to enhance cell viability and reduce apoptosis in lipopolysaccharide (LPS)-stimulated A549 cells. Furthermore, morusin alleviated inflammation by decreasing the levels of interleukin-1β (IL-1β), IL-6, and prostaglandin E2 (PGE2) in LPS-challenged A549 cells. In addition, morusin effectively reduced oxidative stress in these cells. Mechanistically, morusin was found to suppress the activation of NLRP3 (nucleotide-binding domain, leucine rich-containing family, pyrin domain containing 3) inflammasome in LPS-stimulated A549 cells. Finally, this study demonstrated for the first time that morusin ameliorates LPS-induced inflammation and oxidative stress in lung epithelial cells by inhibiting both nuclear factor <i>kappa B</i> signaling pathway and NLRP3 inflammasome activation. However, this project was limited to cell experiments, and no animal experiments or clinical verifications were conducted. Our findings suggest that morusin could serve as a promising therapeutic agent for the treatment of ALI.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"112-118"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i4.1365","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute lung injury (ALI) is a pulmonary disorder characterized by severe lung tissue damage and inflammation. Morusin (a flavone, a type of flavonoid; C25H24O6), a flavonoid isolated from mulberry root bark, possesses notable anti-inflammatory and antioxidant properties. However, its regulatory effects on ALI progression remain unclear. This study aimed to investigate whether morusin could mitigate the development of ALI. Morusin was shown to enhance cell viability and reduce apoptosis in lipopolysaccharide (LPS)-stimulated A549 cells. Furthermore, morusin alleviated inflammation by decreasing the levels of interleukin-1β (IL-1β), IL-6, and prostaglandin E2 (PGE2) in LPS-challenged A549 cells. In addition, morusin effectively reduced oxidative stress in these cells. Mechanistically, morusin was found to suppress the activation of NLRP3 (nucleotide-binding domain, leucine rich-containing family, pyrin domain containing 3) inflammasome in LPS-stimulated A549 cells. Finally, this study demonstrated for the first time that morusin ameliorates LPS-induced inflammation and oxidative stress in lung epithelial cells by inhibiting both nuclear factor kappa B signaling pathway and NLRP3 inflammasome activation. However, this project was limited to cell experiments, and no animal experiments or clinical verifications were conducted. Our findings suggest that morusin could serve as a promising therapeutic agent for the treatment of ALI.
期刊介绍:
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.